Welcome to our dedicated page for Alector news (Ticker: ALEC), a resource for investors and traders seeking the latest updates and insights on Alector stock.
Alector, Inc. (NASDAQ: ALEC) is a late-stage clinical biotechnology company headquartered in South San Francisco, California, focused on therapies for neurodegenerative diseases. News about Alector often centers on its clinical trials, platform advances, and corporate decisions that shape the development of its pipeline.
Investors and followers of ALEC can use this news feed to track updates on latozinemab (AL001) for frontotemporal dementia due to GRN mutations, including the pivotal INFRONT-3 Phase 3 trial and subsequent decisions to discontinue extension studies after the trial did not meet its clinical co-primary endpoint. Coverage also includes developments in nivisnebart (AL101/GSK4527226), the PROGRESS-AD Phase 2 trial in early Alzheimer’s disease, and Alector’s collaboration with GSK around progranulin-elevating monoclonal antibodies.
Another recurring theme in Alector news is progress on the Alector Brain Carrier (ABC) blood-brain barrier platform and its ABC-enabled programs. Articles highlight preclinical candidates such as AL137, an anti-amyloid beta antibody for Alzheimer’s disease; AL050, a GCase enzyme replacement therapy for Parkinson’s disease; and siRNA programs like ADP064-ABC, ADP062-ABC, and ADP065-ABC targeting tau, alpha-synuclein, and NLRP3, respectively.
Corporate updates reported in press releases and 8-K filings include workforce reductions to align resources with strategic priorities, leadership transitions such as the appointment of Neil Berkley as Chief Financial Officer while continuing as Chief Business Officer, and participation in healthcare and CNS therapeutics conferences. Earnings releases and business updates provide additional context on collaboration revenue, research and development spending, and cash runway. Bookmark this page to follow how clinical data, platform progress, and corporate actions influence Alector’s trajectory in neurodegeneration.
Alector reported Q3 2024 financial results with collaboration revenue of $15.3 million and a net loss of $42.2 million. The company maintains a strong cash position of $457.2 million, providing runway through 2026. Key clinical updates include: the INVOKE-2 Phase 2 trial data for AL002 in early Alzheimer's disease expected in 2024, with 98% participant retention in long-term extension; INFRONT-3 Phase 3 trial for latozinemab in FTD-GRN progressing with enrollment completed; and PROGRESS-AD Phase 2 trial for AL101 reaching over one-third of target enrollment. The company reaffirmed 2024 guidance with expected collaboration revenue of $60-70 million.
Alector (Nasdaq: ALEC) presented baseline characteristics for its pivotal INFRONT-3 Phase 3 clinical trial at the 14th International Conference on Frontotemporal Dementias. The trial evaluates latozinemab, a novel monoclonal antibody, for treating frontotemporal dementia with progranulin gene mutation (FTD-GRN). Key points:
- 119 participants enrolled (103 symptomatic, 16 at-risk carriers)
- Mean age: 62.1 years
- 51.3% female, 84.9% Caucasian
- Symptomatic cohort mean CDR plus NACC FTLD-SB score: 6.9
- Mean serum neurofilament light chain: 73.0 pg/mL
The baseline characteristics suggest a representative study population, enabling effective testing of latozinemab in FTD-GRN. The trial, completed enrollment in October 2023, is ongoing with a 96-week treatment duration.
Alector (Nasdaq: ALEC), a clinical-stage biotechnology company focused on immuno-neurology, has announced its participation in three upcoming healthcare conferences in September 2024. The company will be present at:
- Morgan Stanley 22nd Annual Global Healthcare Conference on September 5
- H.C. Wainwright 26th Annual Global Investment Conference on September 9
- 2024 Cantor Global Healthcare Conference on September 17
All events will take place in New York City, featuring fireside chats with Alector's management. Webcasts of these presentations will be available on Alector's investor relations website, with replays accessible for 90 days after each event.
Alector (NASDAQ: ALEC) reported Q2 2024 financial results and provided a business update. Key highlights include:
- Data from INVOKE-2 Phase 2 trial of AL002 in early Alzheimer's disease expected in Q4 2024
- Latozinemab INFRONT-3 Phase 3 trial progressing well after FDA Breakthrough Therapy Designation
- $503.3 million in cash, providing runway through 2026
- Q2 revenue of $15.1 million, down from $56.2 million in Q2 2023
- Net loss of $38.7 million ($0.40 per share) compared to net income of $1.4 million in Q2 2023
- 2024 revenue guidance of $60-70 million maintained
- R&D expenses expected to be $210-220 million
The company remains focused on its immuno-neurology programs and proprietary Alector Brain Carrier technology platform.
Alector (Nasdaq: ALEC), a clinical-stage biotechnology company focused on immuno-neurology, has announced a conference call and webcast scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT. The event will discuss second quarter 2024 results and provide a mid-year business update. A press release detailing Q2 results will be issued before the call. The webcast will be available on Alector's investor relations website, with a 30-day replay option. Phone participants must register online to receive dial-in details and a personal PIN for access.
Alector presented baseline characteristics for the INVOKE-2 Phase 2 clinical trial of AL002, a TREM2 agonist, at AAIC® 2024. The trial, involving 381 participants with early Alzheimer's disease (AD), is the first global Phase 2 study evaluating a TREM2 agonist's safety and efficacy in slowing AD progression. Key points:
- Median age: 71 years (range: 51-85)
- 78% of participants ≥65 years old
- 50% female, 94% Caucasian
- 67% with mild cognitive impairment, 33% with mild dementia
- 59% heterozygous APOE e4 carriers
- All participants confirmed amyloid-positive
Results are expected in Q4 2024, with a long-term extension study ongoing. The baseline data confirm a representative study population for testing AL002's effects in early AD.
Alector Inc (Nasdaq: ALEC) announced presentations on its TREM2 and progranulin programs at the upcoming Alzheimer's Association International Conference® 2024 (AAIC®). The event will be held online and in Philadelphia from July 28 to August 1, 2024.
Key presentations include:
- Two posters on the AL002 TREM2 program, developed with AbbVie, focusing on the INVOKE-2 phase 2 study in early Alzheimer's disease.
- Three posters on progranulin programs (latozinemab and AL101/GSK4527226), developed with GSK, covering plasma biomarkers, the PROGRESS-AD phase 2 study, and genetics related to Alzheimer's disease.
These presentations highlight Alector's ongoing efforts in immuno-neurology and Alzheimer's disease research.
Alector (Nasdaq: ALEC), a clinical-stage biotechnology company specializing in immuno-neurology, will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024. The event will be held virtually, and Alector's management will participate in a corporate presentation. Interested parties can access the webcast on the 'Events & Presentations' page of the Alector website starting at 7:00 a.m. ET. A replay of the presentation will be available on the website for 90 days post-event.
Alector, a clinical-stage biotech firm specializing in immuno-neurology, is set to host a virtual Research and Development event on June 18, 2024. The event will highlight the Alector Brain Carrier, a novel blood-brain barrier (BBB) technology platform. This platform is integral to the company’s upcoming product candidates and research initiatives. The session will feature insights from Alector's management and Dr. Zhiqiang An, an expert in BBB modulation. Participants can register on Alector's website, and a live Q&A will follow the presentation. A replay will be accessible for 90 days post-event.
Alector (Nasdaq: ALEC), a clinical-stage biotechnology company specializing in immuno-neurology, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. The event is scheduled for Monday, June 10, 2024, at 1:20 p.m. ET. A live webcast will be accessible via the Investors section of Alector's website, with a replay available for 90 days post-event.
FAQ
What is the current stock price of Alector (ALEC)?
What is the market cap of Alector (ALEC)?
